Characterizing cancer and COVID-19 outcomes using electronic health records.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
08
2021
accepted:
11
04
2022
entrez:
4
5
2022
pubmed:
5
5
2022
medline:
7
5
2022
Statut:
epublish
Résumé
Patients with cancer often have compromised immune system which can lead to worse COVID-19 outcomes. The purpose of this study is to assess the association between COVID-19 outcomes and existing cancer-specific characteristics. Patients aged 18 or older with laboratory-confirmed COVID-19 between June 1, 2020, and December 31, 2020, were identified (n = 314 004) from the Optum® de-identified COVID-19 Electronic Health Record (EHR) derived from more than 700 hospitals and 7000 clinics in the United States. To allow sufficient observational time, patients with less than one year of medical history in the EHR dataset before their COVID-19 tests were excluded (n = 42 365). Assessed COVID-19 outcomes including all-cause 30-day mortality, hospitalization, ICU admission, and ventilator use, which were compared using relative risks (RRs) according to cancer status and treatments. Among 271 639 patients with COVID-19, 18 460 had at least one cancer diagnosis: 8034 with a history of cancer and 10 426 with newly diagnosed cancer within one year of COVID-19 infection. Patients with a cancer diagnosis were older and more likely to be male, white, Medicare beneficiaries, and have higher prevalences of chronic conditions. Cancer patients had higher risks for 30-day mortality (RR 1.07, 95% CI 1.01-1.14, P = 0.028) and hospitalization (RR 1.04, 95% CI 1.01-1.07, P = 0.006) but without significant differences in ICU admission and ventilator use compared to non-cancer patients. Recent cancer diagnoses were associated with higher risks for worse COVID-19 outcomes (RR for mortality 1.17, 95% CI 1.08-1.25, P<0.001 and RR for hospitalization 1.10, 95% CI 1.06-1.14, P<0.001), particularly among recent metastatic (stage IV), hematological, liver and lung cancers compared with the non-cancer group. Among COVID-19 patients with recent cancer diagnosis, mortality was associated with chemotherapy or radiation treatments within 3 months before COVID-19. Age, black patients, Medicare recipients, South geographic region, cardiovascular, diabetes, liver, and renal diseases were also associated with increased mortality. Individuals with cancer had higher risks for 30-day mortality and hospitalization after SARS-CoV-2 infection compared to patients without cancer. More specifically, patients with a cancer diagnosis within 1 year and those receiving active treatment were more vulnerable to worse COVID-19 outcomes.
Identifiants
pubmed: 35507598
doi: 10.1371/journal.pone.0267584
pii: PONE-D-21-28114
pmc: PMC9067885
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0267584Subventions
Organisme : NCI NIH HHS
ID : R21 CA231904
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
J Clin Oncol. 2020 Nov 20;38(33):3914-3924
pubmed: 32986528
Ther Adv Med Oncol. 2020 Sep 14;12:1758835920956803
pubmed: 32968429
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Cancer Discov. 2020 Oct;10(10):1514-1527
pubmed: 32699031
JNCI Cancer Spectr. 2021 Jan 06;5(1):pkaa090
pubmed: 33604509
Front Oncol. 2021 Mar 25;11:652535
pubmed: 33842366
Ann Hematol. 2021 Feb;100(2):383-393
pubmed: 33159569
Ann Oncol. 2020 Aug;31(8):1088-1089
pubmed: 32330541
Nat Cancer. 2020 Aug;1(8):784-788
pubmed: 35122051
JAMA Netw Open. 2020 Dec 1;3(12):e2029058
pubmed: 33301018
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
BMJ. 2021 Mar 9;372:n579
pubmed: 33687922
J Hematol Oncol. 2020 Jun 10;13(1):75
pubmed: 32522278
Lancet Oncol. 2020 Jul;21(7):904-913
pubmed: 32479787
PLoS Med. 2020 Sep 10;17(9):e1003321
pubmed: 32911500
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
J Natl Cancer Inst. 2021 Jun 1;113(6):691-698
pubmed: 33031532
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
JAMA Oncol. 2021 Jun 17;:
pubmed: 34137793
Nat Med. 2020 Aug;26(8):1218-1223
pubmed: 32581323
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524